{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-000580","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.948060+00:00","generated_at":"2026-06-20T19:19:13.673747+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galectin completes enrollment in NAVIGATE Phase 2b/3 belapectin study for NASH cirrhosis","bullets":["309 patients randomized to date; expects 325-340 total by early March 2023.","Phase 2b portion studies belapectin 2 mg/kg and 4 mg/kg vs. placebo (1:1:1).","Primary endpoint: primary prevention of esophageal varices in NASH cirrhosis with portal hypertension.","Interim analysis results expected in Q4 2024 after 18-month treatment period.","Study recruited patients across 14 countries and five continents."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-000580","json":"https://secwatch.observer/filing/0001140361-23-000580.json","markdown":"https://secwatch.observer/filing/0001140361-23-000580.md","text":"https://secwatch.observer/filing/0001140361-23-000580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123000580/0001140361-23-000580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123000580/brhc10046311_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:19:13.673747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}